The Cancer Letter

Inside information on cancer research and drug development

Clinical Roundup

KEYNOTE-695 study: Tavo + Keytruda demonstrate 30% ORR in anti-PD-1 checkpoint refractory metastatic melanoma

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

In a phase IIb study, Tavo (tavokinogene telseplasmid) in combination with Keytruda (pembrolizumab) led to a 30% overall response rate in the first 54 out of 100 planned patients who have rigorously defined anti-PD1 checkpoint resistant metastatic melanoma.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Guest Editorial

Rathmell: My mentor recognized a cliff I was going to fall off before I did.
“He was there to stand with me while I fell, and then made me look up and see that I needed to lean into the experience.”

I was really excited to get to talk about the role that mentorship plays in women’s leadership development. It’s a topic that I’ve thought a lot about, and also that I’ve benefitted from, and that I think is not always applied with enough intention. There is an art to mentorship, and I want to share some of how that has helped me navigate career transitions and pivot to leadership roles.
By W. Kimryn Rathmell
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account